Join OnKure Therapeutics for a virtual key opinion leader (KOL) event featuring Benjamin F. Cravatt, PhD (The Scripps Research Institute) and Robert Abraham, PhD (Engine Biosciences), who will join company management to discuss the significance of selectivity and the Company’s structure-based drug design enabling the discovery of allosteric pan-mutant PI3Kα inhibitors.

Management will provide an overview of the design strategy employed to create OnKure’s portfolio of next-generation pan-mutant PI3Kα inhibitors.

A live question and answer session will follow the formal presentations.